Disclosed herein are "paraxanthine-BHB" compositions including a combination of: (1) paraxanthine; (2) a BHB ketone body component such as beta-hydroxybutyrate (BHB) salts, BHB esters or BHB acid; and (3) optionally a dietetically or pharmaceutically acceptable carrier. A BHB precursor such as 1,3-butanediol can be used in addition to or instead of BHB. Also disclosed herein are methods of using such compositions for producing desired physiological effects, such as enhanced cognitive flexibility, improved sustained attention, improved working memory, and neuroprotection in a mammal. In addition to such improved mental acuity characteristics, the compositions can also beneficially increase resting energy expenditure (resting metabolic rate), enhancing fat loss principally through ketosis while promoting muscle formation and maintenance, as well as modulating lethargy/lightheadedness when entering a ketogenic state.
In various implementations, a composition comprising R-beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof. The composition may include sodium R-beta-hydroxybutyrate salts; potassium R-beta-hydroxybutyrate; and one or more other salts of R-beta-hydroxybutyrate.
A ketone body composition comprising beta-hydroxybutyrate, related compounds (e.g., 1,3-butanediol), and/or one or more other compounds (e.g., butyrate) may be administered to a non-human animal to raise blood ketones and improve animal health. For example, the ketone body composition can be administered to non-human mammal in order to therapeutically or prophylactically treat one or more conditions selected from obesity, muscle atrophy, body composition, gut health, disease, cancer, epilepsy, seizures, Alzheimer's, oxidative stress, vascular disease, disrupted mitochondria, metabolic decline, cognitive decline, brain function, brain metabolism, brain atrophy, mental acuity, neurological disorders, inflammation, joint health, motor control, memory, or mood. The ketone body composition can be encapsulated, incorporated into a microemulsion or into liposomes, agglomerated, processed using masking/flavoring technologies, and/or otherwise processed so as to improve taste and/or reduce organoleptic reactions from the non-human mammal. Example non-human animals include dogs, cats, horses, cattle, sheep, and pigs.
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
4.
KETONE BODY ESTERS OF S-BETA-HYDROXYBUTYRATE AND/OR S-1,3-BUTANEDIOL FOR MODIFYING METABOLIC FUNCTION
Compositions and methods for producing elevated blood levels of ketone bodies and modifying metabolic function in a mammal. Compositions include at least one ester of S-beta-hydroxybutyrate or a non-racemic ester mixture enriched in S-beta-hydroxybutyrate relative to R-beta-hydroxybutyrate and/or a mono- or di-ester of S-1,3-butanediol or a non-racemic ester mixture enriched in S-1,3-butanediol relative to R-1,3-butanediol and at least one ketone body component. The ketone body component includes beta-hydroxybutyrate, acetoacetate, or both. The beta-hydroxybutyrate is R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, or both. When the ketone body component is S-beta-hydroxybutyrate, the 1,3-butanediol is R-1,3-butanediol, S-1,3-butanediol, or both. Compositions may comprise a keto stack of multiple forms of ketone bodies, such as one or more ketone body salts and/or one or more ketone body acids.
Disclosed herein are "ketone body-HMB" or "KB-HMB" compositions including a combination of: (1) hydroxymethyl butyrate; (2) a ketone body component such as beta-hydroxybutyrate (BHB) and/or acetoacetate; and (3) optionally a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such compositions for producing desired physiological effects, such as fat loss, in a mammal. The compositions beneficially enhance fat loss through ketosis while also reducing or eliminating muscle wasting and/or promoting muscle formation.
Beta-hydroxybutyric acid compositions for oral delivery are substantially free of beta-hydroxybutyrate salts and are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and/or as a gel or suspension. By excluding beta-hydroxybutyrate salts (e.g., less than 1% by weight) containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be enriched with the R- or the S-enantiomer, a racemic mixture, pure R-beta-hydroxybutyric acid, or pure S-beta-hydroxybutyric acid.
A ketogenic R-beta-hydroxybutyrate mixed salt-acid composition includes enantiomerically pure R-beta-hydroxybutyric acid and one or more enantiomerically pure R-beta-hydroxybutyrate salts. The R-beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. The enantiomerically pure R-beta-hydroxybutyrate salt(s) are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for increasing ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and an R-beta-hydroxybutyrate mixed salt-acid composition. The composition contains less than 100% by molar equivalents of total enantiomerically pure R-beta-hydroxybutyrate salts and more than 0% by molar equivalents of enantiomerically pure R-beta-hydroxybutyric acid.
An energy-promoting composition includes a stimulant component such as caffeine, a vasodilator component, an energy source including an exogenous ketone body component, and optionally a nootropic component. The separate components beneficially and synergistically interact with one another enhances the overall energy-promoting effect of the composition more rapidly and to a greater degree than if one or more of the components are omitted. The energy-promoting composition is also formulated to minimize the crash effect common to stimulants such as energy drinks.
An autobiotic composition includes a prebiotic component and postbiotic component. The prebiotic component is a substance resistant to digestion in the stomach and small intestine and selectively fermentable by microorganisms in the large intestine. The postbiotic component is a short-chain fatty acid, such as butyric acid, lactic acid, succinic acid, or salt or ester thereof, such as tributyrin. An autobiotic composition beneficially combines the microbiome-enhancing effects of a prebiotic with the intestinal healing effects of a postbiotic to provide overall benefits to digestive health. A seedbiotic component may form part of or be co-administered with the autobiotic composition. Enzymes may form part of or be co-administered with the autobiotic composition to enhance digestion of the prebiotic in the stomach and intestine and/or increase microbiome health. An exogenous ketone body component may form part of or be co-administered with the autobiotic composition.
Ketogenic compositions include a non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the R-enantiomer. The compositions are enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer to provide alternative benefits. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for increasing ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 50.5% to 99.5% by enantiomeric equivalents of R-beta-hydroxybutyrate and from about 49.5% to about 0.5% by enantiomeric equivalents of S-beta-hydroxybutyrate.
Ketogenic compositions include a mixture of optically pure S-beta-hydroxybutyrate salts and acid(s) or non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contains from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.
Ketogenic compositions including a beta-hydroxybutyrate mixed salt-acid are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The beta-hydroxybutyrate mixed salt-acid is formulated to provide a biologically balanced set of cationic electrolytes and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes beta-hydroxybutyric acid and at least two beta-hydroxybutyrate salts selected from sodium, potassium, calcium, and magnesium. The beta-hydroxybutyric acid fraction of the mixed salt-acid composition is more rapidly absorbed and utilized, can improve taste, and can provide a lower pH composition without having to acid citric or other edible acid. The beta-hydroxybutyrate composition may include transition metal cations (e.g., zinc or iron), one or more beta-hydroxybutyrate-amino acid salts, a short-, medium-, or long chain fatty acid source, vitamin D3, flavorant, and excipients.
Ketogenic compositions include a racemic mixture of R- and S-beta-hydroxybutyric acids and a racemic mixture of R- and S-beta-hydroxybutyrate salts. The compositions contain the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved and yet contain an equivalent amount of the S-enantiomer to provide alternative benefits. The R- and S-beta-hydroxybutyric acids are more rapidly absorbed and utilized by the body than salts or esters, enhance taste, and reduce the need to include citric acid or other edible acids. The R- and S-beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. The ketogenic composition may contain a dietetically or pharmaceutically acceptable carrier and a racemic mixture of R- and S-beta-hydroxybutyrate salts and acids. The composition contains less than 100% by molar equivalents of total R,S-beta-hydroxybutyrate salts and more than 0% by molar equivalents of R,S-beta-hydroxybutyric acids.
Disclosed herein are "ketannabis" (or "ketonnabis") compositions including a combination of: (1) tetrahydrocannabinol (THC); (2) a ketone body component such as beta-hydroxybutyrate (BHB) and/or acetoacetate; and (3) a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such ketannabis compositions for producing desired physiological effects. The ketannabis compositions beneficially enhance the euphoric effects of THC without aggravating common side effects or even acting to reduce common side effects such as anxiety, disruption of short-term memory, appetite increases, heart rate increases, and blood pressure changes.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
15.
COMPOSITIONS AND METHODS FOR DELIVERING CANNABIDIOL AND KETONE BODIES
Disclosed herein are "ketonnabidiol" or "ketannabidiol" compositions including a combination of: (1) cannabidiol (CBD) and/or cannabidiolic acid (CBDA); (2) a ketone body component such as beta-hydroxybutyrate (BHB) and/or acetoacetate; and (3) a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such ketonnabidiol compositions for producing desired physiological effects, such as fat loss, in a mammal. The ketonnabidiol compositions beneficially enhance fat loss through ketosis while also reducing the duration and/or severity of unpleasant "keto flu" symptoms typically associated with ketosis.
Ketogenic compositions including beta-hydroxybutyrate (beta-hydroxybutyrate) and acetoacetate are formulated to induce, promote, or sustain ketosis in a mammal. The combined beta-hydroxybutyrate/acetoacetate compositions include an amount of acetoacetate that limits the reduction in available NAD+ in a subject without causing the formation of excess acetone in the bloodstream. In some aspects a composition for promoting and/or sustaining ketosis in a mammal contains a dietetically or pharmaceutically acceptable carrier and a beta-hydroxybutyrate/acetoacetate mixture of about 5% to about 45% acetoacetate by weight of the mixture and about 55% to about 95% beta-hydroxybutyrate by weight of the mixture.
Ketogenic compositions enriched with the S-enantiomer of beta-hydroxybutyrate (BHB), including a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate, are formulated to control ketone body levels in a subject. The non-racemic mixture of BHB is enriched with the S-enantiomer to modulate the effect of ketone bodies in the subject and control the rate at which ketosis is achieved. In some aspects a composition for controlling ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate, wherein the non-racemic mixture contains from about 52% to 99% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer and from about 48% to about 1% by enantiomeric equivalents of R-beta-hydroxybutyrate enantiomer.
Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the R-enantiomer are formulated to increase ketone body level in a subject. The non-racemic mixture of BHB is enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer sufficient to provide alternative benefits as discussed herein. In some aspects a composition for increasing ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 55% to 98% by enantiomeric equivalents of the R-beta-hydroxybutyrate and from about 45% to about 2% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer.
Ketogenic compositions including a beta-hydroxybutyrate (BHB) mixed salt are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts of at least sodium, potassium, calcium, and magnesium. The BHB salts may also include at least other component such as a BHB compound containing other cations, such as transition metal cations (e.g., zinc or iron), a BHB-amino acid salts, medium chain fatty acid source, vitamin D3, flavorant, or other excipient.
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A61K 31/22 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine
brevets